Conference abstractPublished 28 Nov 2016
Efficacy, safety, economy and regulatory consequences of antiviral agents
PD Science LLC, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
There are three primary determinants of the success for the development of any therapeutic new drugs: Efficacy, Safety and Economy without an exception. The first two priorities determine the usefulness and the third determines affordability and beneficial to a large number of people and yet at reasonable cost and financial return to the pharmaceutical developers. Hundreds of thousands of scientists are searching for potent and effective compounds and equally important to pursue low toxicity and tolerable side effects. For anti-viral agents such as AIDS therapy, several unique aspects need to be considered: The known etiological pathogens and its life cycle steps for targeting, such as HIV; HIV has high mutation rates that resulted in drug resistance; There are only very limited and costly animal models available so that need to stress quantitative and sensitive in vitro evaluation of candidate compounds for preclinical development and clinical follow-ups. Many of the above conditions have been met, but many others remain difficult and pose uncertainties. For today’s discussion, the author would like to focus on the following questions: Why we need drug combinations such as cocktails for antivirals? How to design and quantitatively determine and rank them with computerized simulations? Are the currently approved anti-HIV combination patents and their FDA approved anti-HIV products really represent the better or the best therapeutic products? All the above questions will be discussed and answered by the unified theory of the median-effect equation of the mass-action law, the combination-index theorem and their computerized simulations using the CompuSyn software.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Antivirals & Antiretrovirals
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ting-Chao Chou”
